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Cost-Effectiveness of Coronary Computed
Tomography and Cardiac Stress Imaging
in the Emergency Department
A Decision Analytic Model Comparing Diagnostic Strategies for Chest Pain
in Patients at Low Risk of Acute Coronary Syndromes
Virginia L. Priest, BS,* Paul A. Scuffham, PHD,* Rory Hachamovitch, MS, MD,‡
Thomas H. Marwick, MD, PHD†‡
Brisbane, Queensland, Australia; and Cleveland, Ohio
Emergency department presentations with chest pain are expensive and often unrelated to coronary
artery disease (CAD). Coronary computed tomographic angiography (CTA) may allow earlier discharge
of low-risk patients, resulting in cost savings. We modeled clinical and economic outcomes of diagnostic
strategies in patients with chest pain and at low risk of CAD: exercise electrocardiography (ECG), stress
single-photon emission computed tomography (SPECT), stress echocardiography, and a CTA strategy
comprising an initial CTA scan with conﬁrmatory SPECT for indeterminate results. Our results suggest
that a 2-step diagnostic strategy of CTA with SPECT for intermediate scans is likely to be less costly and
more effective for the diagnosis of a patient group at low risk of CAD and a prevalence of 2% to 30%.
The CTA strategies were cost saving (lower costs, higher quality-adjusted life-years) compared with
stress ECG, echocardiography, and SPECT. Conﬁrming intermediate/indeterminate CTA scans with
SPECT results in cost savings and quality-adjusted life-year gains due to reduced hospitalization of
patients who returned false-positive initial CTA test. However, CTA may be associated with a higher
event rate in negative patients than SPECT, and the diagnostic and prognostic information for the use
of CTA in the emergency department is evolving. Large comparative, randomized, controlled trials of
the different diagnostic strategies are needed to compare the long-term costs and consequences of
each strategy in a population of deﬁned low-risk patients in the emergency department.nnually, more than 6 million patients in
the United States present to emergency
departments (EDs) with chest pain
(1). Conservative diagnostic strate-
gies lead to high admission rates (70%), with
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coronary syndrome (ACS) (2). Admission costs
are augmented by increasing volumes of imag-
ing tests, and the costs to adopt new technol-
ogies. Despite the conservative approach, a
small proportion of patients (0.4% to 4%) with
ACS are misdiagnosed and discharged without
appropriate intervention with double the risk-
adjusted mortality of admitted patients (3).
Failure to diagnose ischemia as the cause of
chest pain is the leading cause of malpractice
suits against ED physicians in the United
States (4). The adoption of dedicated chest
pain centers and chest pain evaluation proto-
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550cols in the ED may extend the group to
include patients with lower probabili-
ties of chest pain.
Patients presenting with chest pain
suggestive of ischemia but with no
history of coronary artery disease
(CAD) and no enzyme or electrocar-
diographic abnormalities are generally
at low risk but can include individuals
with CAD. Of several technologies
available for the diagnostic workup of
these patients, provocative testing such
as exercise electrocardiography (ECG),
exercise or pharmacological echocardi-
ography (echo), and single-photon
emission computed tomography
(SPECT) provide functional informa-
tion about infarction and inducible
ischemia, and the strong evidence base
for these tests in the prediction of
outcomes supports their use in risk
stratification (5,6). However, all these
strategies require a period of observa-
tion before stress testing is safe, and the
healthcare costs associated with these
protocols for acute chest pain evalua-
tion have been estimated to be between
Figure 1. Schematic of the Decision Analytic Tre
Patients can be allocated to 1 of 5 pathways—CT f
node). CT  computed tomography; CVD  cardiovascUS$10 and US$12 billion per year in
the United States (1). Because coronary
computed tomographic angiography
(CTA) does not need cardiac stress
testing, it has the advantage of avoiding
this observation period. Although the
negative predictive value of a normal
scan is reported to be high, the predic-
tive value of a positive test result is
variable and low in the presence of a
low prevalence of CAD. Therefore,
patients with lesions of intermediate
severity may require further investiga-
tions to identify the true positive pa-
tients (7). We sought to identify the
relative cost-effectiveness of diagnostic
imaging strategies in a low-risk patient
population presenting to the ED with
chest pain.
Methods
A decision analytic model using stan-
dard software (TreeAge Pro, William-
stown, Massachusetts) was developed
to estimate and compare the cost and
health outcomes of strategies used to
r 12-Month Disease Progression
wed by selective use of SPECT, or, CT, stress echo, SP
ular disease; ECG  electrocardiogram; SPECT  single-pidentify patients with chest pain who,
on presentation to the ED, are assessed
as having a low risk of CAD (after
exclusion of patients with proven ACS
on the basis of electrocardiographic
changes). Diagnostic strategies com-
pared were exercise ECG, exercise and
pharmacological stress echo, and
SPECT, a CTA-only strategy and
CTA with confirmatory exercise
SPECT for intermediate or indetermi-
nate scans (CTA with SPECT) (Fig.
1). Cost and health outcomes (includ-
ing death and infarction) relating to
CAD and its correct diagnosis were
assessed at 12 months to capture the
immediate consequences of diagnosis
and because published evidence of pa-
tient outcomes is available at this time
point to inform the model.
Disease progression. ACCURACY OF THE
ESTS. Sensitivities and specificities of
the various tests were obtained from
key studies in the literature (Table 1).
The diagnostic accuracy of exercise
ECG was sourced from relevant
guidelines, and those for stress echo
or stress ECG (summarized in a single clonede fo
ollo ECT
hoton emission computed tomography.
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551and SPECT were sourced from a
large published meta-analysis (5).
The accuracy of CTA was sourced
from a published trial of its use in the
ED setting (8). The prevalence, or
pre-test probability, of CAD was var-
ied from 2% to 30%.
POSITIVE DIAGNOSTIC TEST RESULTS.
Patients testing positive proceeded to
invasive coronary angiography. For the
CTA with SPECT strategy, positive
results for CTA were classified into
high-grade stenoses (75% luminal di-
ameter; incidence, 8%) and intermedi-
ate/indeterminate stenoses. All patients
with 75% stenoses then underwent
invasive coronary angiography, with
the remainder undergoing a period of
observation and confirmatory SPECT
(7). Positive findings on angiography
were associated with costs and health
outcomes for the treatment of CAD
and an increased risk of cardiovascular
events (4.6% per annum) compared
with patients judged normal on diag-
nostic tests (9). Patients with positive
diagnostic tests who subsequently
tested negative on angiography were
Table 1. Probabilities and Model Structure
Test Accuracy (First Authors, Year [Ref. #])
ECG (Gaibazzi et al., 2011 [12])
SPECT (Heijenbrok-kal et al., 2007 [5])
Exercise
Adenosine
Dipyridamole
Dobutamine
Echo (Heijenbrok-kal et al., 2007 [5])
Exercise
Adenosine
Dipyridamole
Dobutamine
CTA (Meijboom et al., 2007 [8])
12-month cardiac event rates
Test Strategy
n
Initial negative diagnostic test, %
In patients who test positive on invasive CA (9)
In patients who test negative on invasive CA (10)
CA  coronary angiography; CTA  computed tomograph
computed tomography.assumed to have a cardiovascular event mrate of 0.6% per annum compared with
patients with normal test results (10).
NEGATIVE DIAGNOSTIC TEST RESULTS.
Patients with negative test results on
the initial screen were expected to be
discharged from the ED without fur-
ther investigation. For the base case
analysis, the accrued event rates in
these patients at 12 months were 0.58%
for SPECT and 1.03% for echo (11).
Comparable results for CTA and ECG
were calculated using the data from 2
studies that compared the outcomes in
patients tested with stress echo and stress
ECG (12) and 1 in which all patients
were tested with SPECT and CTA (13).
CARDIOVASCULAR EVENTS. For those
who experienced an event during the
follow-up period, the risk of mortality
was assumed to be 7% (14).
COSTS. All costs were converted to
010 values using the U.S. Consumer
rice Index for medical care (Table 2).
osts associated with diagnostic strat-
gies were calculated from average na-
ional reimbursement in the United
tates using Current Procedural Ter-
No. Studied Methods
11,691 MA of 68 studies
5,786 MA of 55 studies
2,132 MA of 11 studies
1,434 MA of 58 studies
1,066 MA of 102 studies
7,787 MA of 48 studies
1,194 MA of 14 studies
9,341 MA of 23 studies
18,142 MA of 16 studies
33 Diagnosis conﬁrmed with inv
CTA (13) ECG (12)
517 536
0.95 2.97
ngiography; ECG  electrocardiography; Echo  echocardioinology codes and Clinical Classifica-ions Software (15,16). Because of the
omposite contribution of evaluation,
onitoring, and therapies, the cost of
bservation was based on the average
eimbursement at our facility. Patients
ositive on angiography were assumed
o incur an average cost of $27,539 for
he initial hospitalization and $4,818 in
urther treatment costs in the year after
ischarge (17). The cost of an event
as approximated by the weighted av-
rage of costs associated with relevant
iagnoses as classified by Diagnostic
elated Group codes.
Health-related quality of life. Utility
eights associated with the health
tates in the model were sourced from
he published literature where available
Table 2) (18,19). A disutility of 2% of
ormal health was applied to patients
ith a false-positive diagnosis to ac-
ount for the effects of stress for being
alsely diagnosed with CAD and un-
ergoing angiography.
Results
Costs and outcomes. The average costs,
Sensitivity, % Speciﬁcity, %
67 72
88 69
91 81
90 75
84 75
83 84
79 92
72 95
81 84
e CA 100 80
SPECT (11) Echo (11)
5,946 2,900
0.58 1.03
hy; MA  meta-analysis; SPECT  single photon-emittingasiv
4.8%
0.6%
ic a grapquality-adjusted life-years (QALYs),
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552and comparative cost-effectiveness re-
sults from testing a population with 2%
to 30% prevalence of CAD with each
diagnostic strategy at 12 months are
reported in Table 3.
EFFICACY. In all cases, the CTA with
SPECT strategy accrued slightly
higher QALYs than the CTA-only
strategy because the additional diag-
nostic test ruled out some patients
with false-positive CTA scans who
were spared having to undergo an-
giography. Overall, exercise echo ac-
crued more QALYs than the exercise
SPECT strategy because echo has a
lower rate of false positives. However,
SPECT had a lower incidence of
events than exercise echo in patients
who tested negative. Exercise ECG,
which had the lowest sensitivity and
specificity of the diagnostic strategies
modeled, correspondingly accrued
Table 2. Costs and Utilities Included in the Mod
Description Valu
Costs
ECG 143
SPECT 460
Echo 289
CTA 374
Observation for provocative testing 3,00
Invasive CA 874
Hospital charges 11,5
Myocardial infarction
Average 32,5
Associated with CAD
Initial hospitalization 27,5
1-yr post-discharge 4,81
Total 32,3
Description Utili
uDead 0
uEvent MI during year 1 0.68
uNegative (population norm) 0.87
uTrue-Positive (QoL for angina) 0.72
uFalse-Positive 0.85
*Bundled reimbursement at Cleveland Clinic Chest Pain Uni
CAD coronary artery disease; CC cardiac complications
terminology; DRG diagnostic-related group; HCUPnet ht
on data from the Healthcare Cost and Utilization Project [HC
hospital inpatient and emergency department use); MI 
without; other abbreviations as in Table 1.fewer QALYs. aCOSTS. Costs increased with increas-
ng prevalence of CAD. The strategies
hat included CTA as a first-line test
ere least costly. CTA scans with
PECT were less expensive than the
TA-only strategy due to reduced hos-
ital costs in patients who return a
alse-positive CTA test.
COST-EFFECTIVENESS. The CTA
strategies were cost saving (lower costs,
higher QALYs) compared with exer-
cise stress ECG, echo, and SPECT.
Confirming intermediate/indetermi-
nate CTA scans with SPECT results
in cost savings and QALY gains due
to reduced hospitalization of patients
who returned a false-positive initial
CTA test.
Sensitivity analyses. Sensitivity analyses
ere used to explore differences in the
ype of stress-based test used and vari-
tions in the incidence of event rates
Reference
CPT code: 99091 93015
CPT code: 78451 78452  93015
CPT code: 93350 93015
CPT code: 75574
Averaged for ICD codes 78650,51,52,59*
CPT code: 93454
HCupNet – CCS for diagnostic invasive CA
Weighted average of DRGs 280, 281, 282
Ref. 17
Ref. 17
Reference
—
Ref. 20
Ref. 21
Ref. 20
2% disutility for false-positive diagnosis
r August to October 2010.
 Clinical Classiﬁcation Software; CPT current procedural
hcupnet.ahrq.gov (HCUPnet is an online query system based
that provides access to health statistics and information on
ardial infarction; QoL  quality of life; u  utility; w/o nd costs attributed to each test. cUSE OF PHARMACOLOGICAL STRESS.
Use of pharmacologically induced
stress, rather than exercise, did not
change the order of the results, and the
CTA strategies remained cost saving
compared with stress-based tests. Di-
pyridamole was the least costly agent
for echo, and adenosine performed best
in the SPECT arm (Table 4).
VARIATIONS IN EVENT RATES IN PA-
TIENTS WITH NEGATIVE TEST RE-
SULTS. Increasing the event rate in pa-
tients who test negative on CTA did
not appreciably change the results.
However, the model was limited to the
medical costs incurred for events and
did not incorporate those that may arise
from litigation or malpractice.
CHANGES IN THE RELATIVE COSTS OF
THE DIAGNOSTIC TESTS. At a CAD
prevalence of 5%, CTA with SPECT
was the least expensive strategy up to
a price per CTA scan of $4,600. The
CTA-only strategy was less expensive
than the stress-based tests up to a cost
per scan of $3,500 or if the cost of
observation was greater than $400.
Changes in other cost variables did
not affect the order of the results.
Diagnostic accuracy. The diagnostic
ccuracies of the tests (sensitivity,
pecificity, and the corresponding
ositive and negative predictive val-
es), rather than prognostic outcomes
event rates) at 12 months, were used
o validate the results (Table 5).
PECT has low accuracy and a high
ost differential at low levels of prev-
lence due to its low specificity rate
nd high number of false-positive
esults. However, the high sensitivity
f SPECT confers a low false-
egative rate. The high specificity of
cho produces fewer false positives
nd greater overall accuracy at lower
ost than SPECT, but with a higher
roportion of false negatives due to
ts lower relative sensitivity. Adding ael
e, $
.78
.97
.81
.35
9
.21
78
19
40
8
57
ties
t ove
; CCS
tp://
UP]
myoconfirmatory SPECT test to the
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553CTA strategy improves accuracy, par-
ticularly at low levels of prevalence
when the majority of patients who
test positive on CTA do not have
Table 4. Results of SPECT and Echo Pharmacolo
Diagnostic Strategy Costs, $
Echo
Exercise 7,539
Adenosine 6,430
Dipyridamole 5,988
Dobutamine 7,576
SPECT
Exercise 10,799
Adenosine 8,321
Dipyridamole 9,449
Dobutamine 9,449
Technetium 13,577
Table 3. Results by Diagnostic Accuracy Scenario
Diagnostic Strategy
Prevalence 2% (20 of every 1,000 people have CAD
CTA then SPECT
CTA
Ex Echo
Ex SPECT
Ex ECG
Prevalence 5% (50 of every 1,000 people have CAD
CTA then SPECT
CTA
Ex Echo
Ex SPECT
Ex ECG
Prevalence 10% (100 of every 1,000 people have C
CTA then SPECT
CTA
Ex Echo
Ex SPECT
Ex ECG
Prevalence 20% (200 of every 1,000 people have C
CTA then SPECT
CTA
Ex Echo
Ex ECG
Ex SPECT
Prevalence 30% (300 of every 1,000 people have C
CTA then SPECT
CTA
Ex Echo
Ex ECG
Ex SPECT
Dominated strategy is inferior to dominant comparator (ha
other abbreviations as in Tables 1 and 2.Abbreviations as in Tables 1 and 3.CAD. CTA with SPECT is the least
costly strategy at the point of diagno-
sis and associated with considerable
savings due to reduced observation
l Stress (CAD Prevalence 5%)
Ys No. of Events in Negative Patients
79 8
96 9
06 9
79 8
48 4
81 4
66 4
66 4
05 3
ith CAD Prevalence of 2% to 30%
Costs, $ QALYs IC
2,382 0.8648 —
3,933 0.8613 Dom
6,710 0.8617 Dom
10,111 0.8582 Dom
9,762 0.8555 Dom
3,464 0.8602 —
4,862 0.8568 Dom
7,539 0.8579 Dom
10,799 0.8548 Dom
10,430 0.8523 Dom
5,268 0.8526 —
6,409 0.8493 Dom
8,924 0.8515 Dom
11,957 0.8491 Dom
11,555 0.8468 Dom
8,875 0.8373 —
9,505 0.8344 Dom
11,708 0.8386 $2.2
14,316 0.8356 Dom
13,853 0.8373 Dom
12,483 0.8373 —
12,600 0.8344 Dom
14,515 0.8386 $57
16,742 0.8356 Dom
16,223 0.8373 Dom
th higher costs and lower QALYs); Ex exercise; ICER incremand hospitalization costs compared
with the stress-based tests.
Discussion
Our results suggest that a diagnostic
strategy of CTA with confirmatory
SPECT for indeterminate scans may
be cost saving in the United States
despite modeling a higher event rate
in patients who test negative on CTA
than SPECT. This work differs from
previous work in its inclusion of ex-
ercise ECG and echo as diagnostic
strategies and prognostic information
for events at 12 months follow-up
from testing.
Coronary CTA in the ED. The results of
this study are consistent with those of
other studies on CTA use in the ED.
No. of Events in Negative Patients
7
ed 7
ed 8
ed 4
ed 17
7
ed 7
ed 8
ed 4
ed 16
7
ed 7
ed 7
ed 3
ed 16
6
ed 6
on 6
ed 14
ed 3
5
ed 5
2 6
ed 12
ed 3
cost-effectiveness ratio; QALYs quality-adjusted life-years;gica
QAL
0.85
0.85
0.86
0.85
0.85
0.85
0.85
0.85
0.85W
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554Goldstein et al. (7), CTA with SPECT
for intermediate scans resulted in lower
costs due to reduced time to diagnosis.
A key limitation is the evidence base;
our study relied on the diagnostic effi-
cacy of CTA as reported by the only
trial conducted in low-risk patients
with acute coronary syndrome using
64-slice CTA (8), and prognostic
events as reported by van Werkhoven et
al. (13) in a prospective observational
study. This highlights the need for
further research to determine the true
diagnostic and prognostic accuracy of
CTA in the ED patient population.
Cost-effectiveness of CTA in the
ED. There is a dearth of comparative
Table 5. Correct Diagnosis Model: Expected Diag
Diagnostic Accuracy
Prevalence  2% (20 patients with CAD)
CTA  SPECT
CTA
Ex Echo
Ex ECG
Ex SPECT
Prevalence  5% (50 patients with CAD)
CTA  SPECT
CTA
Ex Echo
Ex ECG
Ex SPECT
Prevalence  10% (100 patients with CAD)
CTA  SPECT
CTA
Ex Echo
Ex ECG
Ex SPECT
Prevalence  20% (200 patients with CAD)
CTA  SPECT
CTA
Ex Echo
Ex ECG
Ex SPECT
Prevalence  30% (300 patients with CAD)
CTA  SPECT
CTA
Ex Echo
Ex ECG
Ex SPECT
All numbers rounded to nearest whole number.
Abbreviations as in Tables 1, 2, and 3.ffectiveness and cost-effectiveness in- qormation for CTA from clinical trials.
o date, 2 studies have considered
TA as a diagnostic strategy in stable
resentations with CAD (19,20).
adapo et al. (20) reported that in a
ow-risk population presenting with
table chest pain, CTA was associated
ith an increased cost and an incre-
ental cost-effectiveness ratio of
6,400 in men; however, it was cost
aving in women because of the lower
revalence of CAD. Their analysis
redicted that CTA would be associ-
ted with an extended life expectancy
f 10 days in men and 6 days in
omen. Min et al. (21) presented a
ifetime model of costs and conse-
tic Accuracy in a Population of 1,000 Patients at
rage Cost, $ per
tient Diagnosed
True
Positive
False
Positive
1,508 20 16
3,064 20 196
5,900 17 192
8,502 15 414
9,202 18 347
1,952 50 15
3,363 50 190
6,202 42 191
8,719 37 410
9,407 44 340
2,693 100 14
3,861 100 180
6,704 84 189
9,082 75 401
9,750 89 328
4,173 200 13
4,857 200 160
7,710 185 615
9,806 152 382
10,436 178 303
5,654 300 11
5,853 300 140
8,715 255 180
10,531 233 359
11,122 268 278uences in a diagnostic population Mith intermediate (30%) prevalence
f CAD. These authors also report
hat the CTA with confirmatory
PECT strategy is the least expensive
trategy, which is in line with our
ndings (Table 3).
These studies also report that their
nalyses are sensitive to changes in
he accuracy and relative costs of the
iagnostic tests, as well as the preva-
ence of CAD. Despite differences in
iagnostic accuracy among CTA and
xercise ECG, SPECT, and echo, the
ifferences in QALYs across diagnos-
ic strategies at 12 months were small
n this low-risk population. Interest-
ngly, both Ladapo et al. (20) and
erent Levels of Prevalence
True
Negative
False
Negative
Overall
Accuracy, %
964 0 98.43
784 0 80.40
788 3 80.46
565 5 57.99
633 2 65.03
935 0 98.47
760 0 81.00
759 8 80.07
540 13 57.69
610 6 65.41
886 0 98.55
720 0 81.99
711 16 78.87
498 25 57.30
572 11 66.76
787 0 98.70
640 0 83.98
31 0 77.46
418 48 56.98
497 22 69.02
689 0 98.85
560 0 85.97
520 45 77.46
341 67 57.34
422 31 69.02nos Diff
Ave
Pain et al. (21) also found small
T
c
C
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555differences in QALYs across the
strategies in lifetime models.
Our results also demonstrate that it
is important to include prognostic
information to predict longer term
health outcomes of the test rather
than relying solely on diagnostic ac-
curacy information. Given the paucity
of information to inform the CTA
arm of our model, we believe that
further research should be undertaken
to identify its true accuracy (sensitiv-
ity and specificity), and trials with
longer term clinical follow-up to cap-
ture prognostic information in the
form health outcomes and demon-
strating the comparative cost-
effectiveness are needed before wide-
spread adoption of this technology.
Clinical trials currently under way
may provide evidence of the long-
term prognostic value of CTA com-
pared with SPECT, although the re-
sults of our analysis also warrant a
direct comparison of a CTA strategy
with echo, perhaps including a CTA
with confirmatory echo strategy.
Study limitations. Our analysis relied
on assumptions derived from pub-
lished evidence, and decision models
inevitably simplify a complex situa-
tion. Patients re-attending to the ED
with recurrent chest pain are not
Table 6. Key Points of the Study
In contrast to the situation of patients with ambula
grounds, are at low risk of CAD.
The high predictive value of a negative coronary C
engendered interest in the use of this test to ex
In addition to planned deﬁnitive trials, a decision-a
prognostic implications of testing across multipl
The anticipated CTA-based strategy involves immed
diagnostic changes on the electrocardiogram. Pa
undergo additional observation and testing with
In these models of a patient group at low risk of C
compared with a CTA-only strategy, stress ECG,
and the diagnostic and prognostic information f
Abbreviations as in Tables 1 to 3.pated to represent a component of the
patients characterized as having no
CAD. The model does not incorpo-
rate the benefits of revascularization
on potentially reducing ED presenta-
tions in survivors. Finally, although
previous studies categorized different
levels of risk in patients with mild
stenoses and no stenoses (10), the
diagnostic accuracies used in this
study relate to a binary cutoff of
disease severity (6,8).
The time frame for the analysis is
short (12 months). Because data are
available to inform the analysis, less
extrapolation and reliance on assump-
tions are required, which reduces un-
certainty. However, it does not cap-
ture the longer term consequences or
costs from clinical decisions made at
diagnosis. The accuracy and outcome
data for functional testing were de-
rived from the literature, but few of
these studies incorporate newer de-
velopments, such as the use of echo-
cardiographic contrast agents and
gated ventriculography and attenua-
tion correction for SPECT, that may
change the diagnostic performance of
the tests. Indeed, the use of exercise
capacity and heart rate recovery may
improve the performance of ordinary
stress ECG. On the other hand, none
presentations with chest pain, acute presentations m
can, which does not require provocative testing (and
e CAD, shorten hospital stay, and reduce the cost of
tic model could help deﬁne the most cost-effective a
dies.
performance of CTA, without a period of observatio
ts with a completely normal CTA would be discharg
ss SPECT.
and prevalence 2% to 30%, CTA with conﬁrmatory S
, and SPECT. However, CTA may be associated with
e use of CTA in the emergency department is scarctice. Finally, the analysis does not
incorporate issues of radiation expo-
sure, the safety of which with nuclear
and CTA imaging has recently re-
ceived intense scrutiny. CTA can be
performed with low radiation exposure,
and avoidance of radiation is prudent in
younger patients, especially women.
Conclusions
The salient points of this analysis are
summarized in Table 6. The results
indicate that a 2-step diagnostic
strategy of CTA with SPECT for
intermediate scans is likely to be less
costly and more effective than stress-
based regimens such as ECG,
SPECT, and echo. However, the di-
agnostic and prognostic information
for the use of CTA in the ED is
evolving. Large comparative, ran-
domized, controlled trials of the dif-
ferent diagnostic strategies are
needed to compare the long-term
costs and consequences of each test-
ing strategy in a population of defined
low-risk patients.
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